AbbVie (NYSE:ABBV) Releases FY 2025 Earnings Guidance

AbbVie (NYSE:ABBV - Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 11.670-11.870 for the period. The company issued revenue guidance of -. AbbVie also updated its Q2 2025 guidance to 2.840-2.880 EPS.

Analyst Ratings Changes

ABBV has been the subject of several analyst reports. Wall Street Zen lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Morgan Stanley lifted their price target on shares of AbbVie from $241.00 to $250.00 and gave the company an "overweight" rating in a report on Monday, April 28th. Bank of America lifted their price target on shares of AbbVie to $204.00 and gave the company a "hold" rating in a report on Monday, June 9th. Evercore ISI lifted their price target on shares of AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a report on Monday, April 28th. Finally, BNP Paribas raised shares of AbbVie to a "hold" rating in a report on Thursday, May 8th. Eight investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average target price of $211.29.

AbbVie Price Performance

ABBV traded up $4.34 during trading hours on Thursday, hitting $194.96. The company's stock had a trading volume of 6,044,962 shares, compared to its average volume of 6,288,138. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. AbbVie has a 12 month low of $163.81 and a 12 month high of $218.66. The stock has a market cap of $344.38 billion, a price-to-earnings ratio of 82.96, a P/E/G ratio of 1.28 and a beta of 0.48. The business's 50-day moving average price is $187.10 and its 200-day moving average price is $188.78.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business had revenue of $13.34 billion for the quarter, compared to analysts' expectations of $12.91 billion. During the same quarter in the previous year, the business posted $2.31 earnings per share. The business's revenue was up 8.4% compared to the same quarter last year. Sell-side analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.36%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie's dividend payout ratio (DPR) is 279.15%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AbbVie stock. Revolve Wealth Partners LLC increased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 72.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,279 shares of the company's stock after acquiring an additional 3,064 shares during the quarter. Revolve Wealth Partners LLC's holdings in AbbVie were worth $1,294,000 as of its most recent SEC filing. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.